MARATTO

article · Systems Biology in Reproductive Medicine

Diagnostic and surveillance strategies for Marburg virus persistence in the male reproductive tract: insights from Ebola and Zika viruses

Abstract

The recent outbreak of the Marburg virus (MARV) in Rwanda was effectively controlled, but concerns remain regarding the virus's persistence and its long-term effects. MARV can remain in the testes of nonhuman primates, where it harms Sertoli cells and compromises the blood-testis barrier, which may have implications for male infertility. This persistence is aided by immunosuppressive regulatory T cells (Tregs), which allow the virus to evade the immune system. Drawing comparisons with Ebola and Zika viruses, we propose that MARV may contribute to male infertility and recommend further studies on human and nonhuman primate survivors. Quick and precise diagnosis is vital for controlling outbreaks. Current diagnostic methods include RT-PCR, ELISA (for antibody and antigen detection), virus isolation, and electron microscopy. Newer technologies like multiplex real-time PCR and CRISPR-based biosensors (e.g., SHERLOCK) provide faster, more sensitive, and on-site detection, which is especially useful in resource-limited areas. These advancements improve MARV monitoring; however, strict biosafety measures are still necessary due to its classification as a Risk Group 4 pathogen.

Research topics

  • Viral Infections and Outbreaks Research
  • Mosquito-borne diseases and control
  • COVID-19 Impact on Reproduction

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/19396368.2026.2652242

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.